Workshop on Combination Immunotherapy: Where Do We Go From Here?
|
The SITC 2014 Workshop Presentation Archive is supported through a generous contribution from Prometheus Laboratories Inc. Access slide decks and video via the links in the schedule below.
|
 |
Thursday, November 6, 2014 |
|
| 7:00 am – 8:00 am | Breakfast |
| 8:00 am – 8:15 am | Workshop Overview and the Current Immunotherapy Landscape .25 AMA PRA Category 1 Credit™ |
| 8:00 am – 8:05 am | Welcome and Overview Drew M. Pardoll, MD, PhD – Johns Hopkins University |
| 8:05 am – 8:15 am | The Current Immunotherapy Landscape Drew M. Pardoll, MD, PhD – Johns Hopkins University |
| 8:15 am – 9:35 am | Session I: Beyond the Inflamed/Non-Inflamed Classification of the Immune Microenvironment 1.25 AMA PRA Category 1 Credit™ |
| 8:15 am – 8:35 am | Immunoscore in the Era of Cancer Immunotherapies Jerome Galon, PhD – INSERM - Cordeliers Research Center |
| 8:35 am – 8:55 am | Immune-Tumor Interactions to Guide Combination Therapies   Antoni Ribas, MD, PhD – University of California Los Angeles |
| 8:55 am – 9:15 am | PD-L1 IHC in Clinical Decision-Making for Immune Checkpoint Blockade Suzanne L. Topalian, MD – Johns Hopkins University |
| 9:15 am – 9:35 am | Panel Discussion |
| 9:35 am – 10:00 am | Break |
| 10:00 am – 11:40 am | Session II: What does an “Immunologically Inert” Tumor Mean? 1.75 AMA PRA Category 1 Credit™ |
| 10:00 am – 10:20 am | Genomic Approaches to Tumor Specific Immunotherapy Robert D. Schreiber, PhD – Washington University |
| 10:20 am – 10:40 am | Molecular Mechanisms Controlling the T Cell-Inflamed Tumor Microenvironment: Implications for Therapy Thomas F. Gajewski, MD, PhD – University of Chicago |
| 10:40 am – 11:00 am | Inducing T Cell Responses to Cancer by Providing Signal 0’s-DAMPs, PAMPs, and SAMPs and ‘Immunogenicity’ Michael T. Lotze, MD – University of Pittsburgh Cancer Institute |
| 11:00 am – 11:20 am | Effects of Targeted Therapies on the Immune System Jennifer A. Wargo, MD – University of Texas, MD Anderson Cancer Center |
| 11:20 am – 11:40 am | Panel Discussion |
| 11:40 am – 1:00 pm | Lunch |
| 1:00 pm – 2:40 pm | Session III: How to Break Tumor-Induced Immune Suppression 1.75 AMA PRA Category 1 Credit™ |
| 1:00 pm – 1:20 pm | Targeting Tregs in Tumors Dario A. A. Vignali, PhD – University of Pittsburgh |
| 1:20 pm – 1:40 pm | Novel Checkpoint Targets that Bind Nectin and Nectin-Like Ligands Ana Carrizosa Anderson, PhD – Harvard Medical School |
| 1:40 pm – 2:00 pm | Effects of Immunotherapy on the Tumor Microenvironment Susan M. Kaech, PhD – Yale University |
| 2:00 pm – 2:20 pm | Molecular Mechanisms of T Cell Exhaustion E. John Wherry, PhD – University of Pennsylvania |
| 2:20 pm – 2:40 pm | Panel Discussion |
| 2:40 pm – 3:00 pm | Break |
| 3:00 pm – 4:45 pm | Session IV: Ideas for Innovative Combination Approaches in the Future 1.75 AMA PRA Category 1 Credit™ |
| 3:00 pm – 3:20 pm | Targeting Multiple Inhibitory Receptors to Reverse Melanoma-Induced T Cell Dysfunction Hassane M. Zarour, MD – University of Pittsburgh |
| 3:20 pm – 3:40 pm | Cytokine and Anti-Angiogenesis Checkpoint Combinations F. Stephen Hodi Jr., MD – Dana-Farber Cancer Institute |
| 3:40 pm – 4:00 pm | Imprecision Medicine: Combination Immunotherapy Mario Sznol, MD – Yale University |
| 4:00 pm – 4:45 pm | Panel Discussion |
| 4:45 pm – 5:00 pm | Closing Remarks and Wrap-Up Summary .25 AMA PRA Category 1 Credit™ Drew M. Pardoll, MD, PhD – Johns Hopkins University |
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
